Quizartinib is a type II tyrosine kinase inhibitor that is in phase III clinical trials for treatment of acute myeloid leukemias with FLT3 internal tandem duplications (ITDs). This pathway describes FLT3 mutants that display resistance to quizartinib (reviewed in Kazi and Roonstrand, 2019; Daver et al, 2019).
Kazi, JU, Rönnstrand, L
Schlenk, RF, Levis, MJ, Daver, N, Russell, NH
© 2023 Reactome